Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Antihypertensive and metabolic effects of empagliflozin in Ren-2 transgenic rats, an experimental non-diabetic model of hypertension
Silvie Hojná, Hana Rauchová, Hana Malínská, et al.
Biomedicine & Pharmacotherapy (2021) Vol. 144, pp. 112246-112246
Open Access | Times Cited: 16

Showing 16 citing articles:

Endothelial and vascular smooth muscle dysfunction in hypertension
Mariana G. de Oliveira, Wilson Nadruz, Fabíola Z. Mónica
Biochemical Pharmacology (2022) Vol. 205, pp. 115263-115263
Closed Access | Times Cited: 37
In a Prediabetic Model, Empagliflozin Improves Hepatic Lipid Metabolism Independently of Obesity and before Onset of Hyperglycemia
Martina Hüttl, Irena Marková, Denisa Miklánková, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 21, pp. 11513-11513
Open Access | Times Cited: 34
RNA-Seq transcriptome analysis of renal tissue from spontaneously hypertensive rats revealed renal protective effects of dapagliflozin, an inhibitor of sodium-glucose cotransporter 2
Jiangjun Wei, Fangyan Tan, Xianglin Long, et al.
European Journal of Pharmaceutical Sciences (2023) Vol. 189, pp. 106531-106531
Open Access | Times Cited: 13
Cardioprotective Effects of Sodium Glucose Cotransporter 2 Inhibition in Angiotensin II-Dependent Hypertension Are Mediated by the Local Reduction of Sympathetic Activity and Inflammation
Giovanna Castoldi, Raffaella Carletti, Silvia Ippolito, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 13, pp. 10710-10710
Open Access | Times Cited: 12
The treatment with soluble guanylate cyclase stimulator BAY41-8543 prevents malignant hypertension and associated organ damage
Martina Hüttl, Matúš Miklovič, Olga Gawryś, et al.
Journal of Hypertension (2025)
Closed Access
RNA-Seq transcriptomic landscape profiling of spontaneously hypertensive rats treated with a sodium-glucose cotransporter 2 (SGLT2) inhibitor
Fangyan Tan, Xianglin Long, Jianlin Du, et al.
Biomedicine & Pharmacotherapy (2023) Vol. 166, pp. 115289-115289
Open Access | Times Cited: 9
Hepatoprotective and cardioprotective effects of empagliflozin in spontaneously hypertensive rats fed a high-fat diet
Silvie Hojná, Hana Malínská, Martina Hüttl, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 174, pp. 116520-116520
Open Access | Times Cited: 3
Empagliflozin alters lipid metabolism in the myocardium and liver in a prediabetes model with severe dyslipidemia
Denisa Miklánková, Irena Marková, Martina Hüttl, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 3
Beneficial Effects of Empagliflozin Are Mediated by Reduced Renal Inflammation and Oxidative Stress in Spontaneously Hypertensive Rats Expressing Human C-Reactive Protein
Hana Malínská, Martina Hüttl, Irena Marková, et al.
Biomedicines (2022) Vol. 10, Iss. 9, pp. 2066-2066
Open Access | Times Cited: 14
Empagliflozin attenuates radiation-induced hematopoietic damage via NOX-4/ROS/p38 pathway
Qidong Huo, Tongpeng Yue, Wenxuan Li, et al.
Life Sciences (2024) Vol. 341, pp. 122486-122486
Closed Access | Times Cited: 2
Empagliflozin alleviates the development of autoimmune myocarditis via inhibiting NF-κB-dependent cardiomyocyte pyroptosis
Chao Lv, Chongqing Hu, Chuanmeng Zhu, et al.
Biomedicine & Pharmacotherapy (2023) Vol. 170, pp. 115963-115963
Open Access | Times Cited: 6
Empagliflozin Is Not Renoprotective in Non-Diabetic Rat Models of Chronic Kidney Disease
Silvie Hojná, Zoe Kotsaridou, Zdeňka Vaňourková, et al.
Biomedicines (2022) Vol. 10, Iss. 10, pp. 2509-2509
Open Access | Times Cited: 9
Associations of SGLT2 genetic polymorphisms with salt sensitivity, blood pressure changes and hypertension incidence in Chinese adults
Hao Jia, Peng Bao, Shi Yao, et al.
Hypertension Research (2023) Vol. 46, Iss. 7, pp. 1795-1803
Closed Access | Times Cited: 5
Gliflozins in the Treatment of Non-diabetic Experimental Cardiovascular Diseases
Ivana Vaněčková, Josef Zicha
Physiological Research (2024), Iss. Suppl 1, pp. S377-S387
Open Access | Times Cited: 1
Empagliflozin Ameliorates Progression From Prediabetes to Diabetes and Improves Hepatic Lipid Metabolism: A Systematic Review
Md Fahad Hossain, Nawsheen A Khan, Afroza Rahman, et al.
Cureus (2022)
Open Access | Times Cited: 6
Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Nondiabetic Patients with Chronic Kidney Disease: A Review of Recent Evidence
Junhao Lv, Luying Guo, Rending Wang, et al.
Kidney Diseases (2023) Vol. 9, Iss. 5, pp. 326-341
Open Access | Times Cited: 3
Page 1

Scroll to top